A man known as the ‘Living Nostradamus’ has issued a worrying warning about the use of weight-loss drugs.
In the last couple of years, the use of GLP-1 medications for weight loss has exploded, after they were first used for patients with diabetes to help regulate their blood sugar.
It was soon discovered that the medications – including Ozempic, Mounjaro, and Wegovy – could also help curb the appetite, leading to weight loss and increasing off-label use.
While they are proving to be effective, some people have raised concerns about what the long-term effects could be, given that the drugs are still very new.
One of these people is Brazilian seer Athos Salomé, 38, who is known as the ‘Living Nostradamus’ for his uncanny ability to predict global disasters and world events before they happen.
The alleged psychic and prophet had reportedly predicted the Covid-19 pandemic as well as Queen Elizabeth II’s death, among his many prophecies.
Salomé has now shared his predictions for 2026 – and it involves some concerning news for those that are taking weight-loss drugs.
He told Tyla that he foresees an increase in “subclinical pancreatitis” and “medication fatigue” as use of GLP-1 drugs increases.
He added that he believes these medications will “assume a strategic role within health systems from 2026 onwards” as “countries depend on these drugs to contain costs and reduce hospital strain” and they “understand the impact of this dependency”.
Salomé added: “Another concern is medication fatigue after two and a half years of continuous semaglutide use. The phenomenon marks the natural limits of the first generation of GLP-1 drugs. Adjustments will be necessary to maintain both efficacy and safety.”
According to RAND, almost 12% of Americans have used GLP-1 drugs for weight loss, with it most commonly being used by women aged between 50 and 64.
While some may see them as a silver bullet to aid in weight loss, they do come with some nasty side effects, which can include nausea, vomiting, diarrhea, and rapid weight loss can often lead to what has become known as ‘Ozempic face’ – where the skin on the face hollows and sags, per Harvard Health.
Pancreatitis is also a known potential side-effect from GLP-1 agonists, so Salomé’s prediction could very well come true in the coming months.
Salomé also predicted that “the era of Ozempic and Mounjaro’s isolated dominance” is coming to an end as the weight-loss drug sector has “entered a cycle of continuous innovation”.
He added: “The challenge now is understanding how governments will manage this progress. The arrival of Chinese companies in the European market represents a strategic shift.
“I see Europe seeking to reduce its dependence on Novo Nordisk and Eli Lilly. The decision involves considerations of energy, security and economic autonomy.
“I believe that nations able to reduce healthcare spending will gain geopolitical advantage. Obesity medications are beginning to function as diplomatic tools. The issue has reached the agenda of international blocs.”
